Ayca Dundar

39PUBLICATIONS

227CO-AUTHORS

PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (39)

Sort by Publication Date:

|Jun 18, 2026

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

|Mar 25, 2026

Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.

Emmanuel S Antonarakis, Qing Cao, Victoria Catharine

|Mar 12, 2026

Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis.

Charles Swanton, Alan Bryce, Allen L Cohn

|Feb 26, 2026

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Dec 04, 2025

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.

Nicolas Sayegh, Ryon P Graf, Umang Swami

|May 02, 2025

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.

Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi

Pageof 7

Frequent Collaborators

8 joint publications

Emmanuel S Antonarakis

Oliver Sartor

Michael Morris

Himisha Beltran

Rana R Mckay

Rahul R Aggarwal

Andrew J Armstrong

Scott Tagawa

Heather H Cheng

Pedro C Barata

Frequent Collaborators

8 joint publications

Emmanuel S Antonarakis

7 joint publications

Oliver Sartor

6 joint publications

Michael Morris

5 joint publications

Himisha Beltran